• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical-investing

    OpGen Announces Closing of Public Offering of Common Stock

    Jocelyn Aspa
    Mar. 29, 2019 09:03AM PST
    Pharmaceutical Investing

    OpGen (NASDAQ:OPGN) has announced it has closed its underwritten public offering of nine million shares of its common stock at US$0.60 per share. As quoted in the press release: All of the shares were sold by OpGen. The aggregate gross proceeds to OpGen from the offering, before deducting the underwriting discount and commissions and offering …

    OpGen (NASDAQ:OPGN) has announced it has closed its underwritten public offering of nine million shares of its common stock at US$0.60 per share.

    As quoted in the press release:

    All of the shares were sold by OpGen. The aggregate gross proceeds to OpGen from the offering, before deducting the underwriting discount and commissions and offering expenses, were approximately $5.4 million.

    Aegis Capital Corp. acted as the sole book-running manager for the offering.

    The shares were issued pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC). A final prospectus was filed with the SEC on March 26, 2019. A copy of the final prospectus relating to the offering, when available, may be obtained by contacting Aegis Capital Corp., 810 7th Avenue, 18th Floor, New York, NY 10019, (212) 813-1010 or by accessing the SEC’s website, www.sec.gov.

    Click here to read the full press release.

    public-offeringpharmaceutical-investingnasdaq-opgn
    The Conversation (0)

    Go Deeper

    AI Powered

    Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    PolarityTE Announces Public Offering of Common Stock

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    InMed Pharmaceuticals

    InMed Pharmaceuticals (INM)
    INM

    Cardiol Therapeutics

    Cardiol Therapeutics (CRDL:CC)
    CRDL:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES